This study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization programs (NIPs) on vaccine-type and non-vaccine type invasive disease (IPD) incidence across all ages using surveillance data.We identified countries (Australia, Canada, England Wales, Israel, US) with IPD active data that introduced seven-valent PCV (PCV7) followed by PCV13, which also reported serotype- age group-specific incidence. We extracted serotype...

Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a 1+1 (1 primary dose) pediatric schedule in United Kingdom (UK). Higher-valency PCVs, 15-valent PCV (PCV15), or 20-valent (PCV20) might be considered to expand serotype coverage. We evaluated cost-effectiveness of PCV20 PCV15 using either 2+1 (2 doses) for immunization UK. Using dynamic transmission model, we simulated future disease incidence and costs PCV13 1+1, 2+1, schedules from UK National Health...

The 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix) was introduced into the Dutch pediatric national immunization program (NIP) starting in 2011. However, there is substantial disease burden due to increases non-PCV10 covered serotypes. Higher-valent vaccines for pediatrics (PCV13, PCV15, and PCV20) may alleviate much of remaining upon implementation through broader serotype coverage. This article assesses public health impact different vaccination strategies (switching PCV13,...

Pneumococcal disease, which presents a substantial health and economic burden, is prevented through pneumococcal vaccination programs. We assessed the impact of switching from 13-valent-based (PCV13) to lower 10-valent-based (PCV10-GlaxoSmithKline [GSK] or PCV10-Serum Institute India [SII]) higher-valent (PCV15 PCV20) programs in South Africa. A previously published decision-analytic model was adapted African setting. Historical invasive disease (IPD) incidence data were used project IPD...

Von Willebrand Disease (vWD) is the most common congenital bleeding disorder, with an estimated prevalence in Spain of 0.01%. The aim was to assess cost-utility Haemate-P compared present alternatives treatment vWD Spain. A Markov model developed Microsoft Excel estimate cost-effectiveness various treatments for over a lifetime horizon. Transition probabilities among health states were based on age and number events. Treatment strategies included Haemate-P, Fanhdi, Wilate long-term...

Pneumococcal conjugate vaccines (PCVs) have been available in Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization program throughout all Canadian provinces by 2011. The use of PCVs has dramatically reduced burden pneumococcal disease Canada. As a result, decision-makers may consider switching from more costly, higher-valent vaccine lower-cost, lower-valent an attempt allocate funds for other programs. We assessed health and economic impact vaccination PCV13...

Intracerebral hemorrhage (ICH) is among the most costly and debilitating forms of stroke. Results from a recent Phase IIb clinical trial demonstrate that administration recombinant activated factor VII (rFVIIa) reduces ICH mortality improves functional outcome. In current analysis, we examine cost-effectiveness early treatment with rFVIIa for in United States.A decision-analytic model was developed to estimate lifetime costs outcomes associated at doses 40, 80 160 microg/kg compared standard...

Background: Bronchodilators such as long-acting muscarinic antagonists (LAMAs) and β 2 -agonists (LABAs) are central to the pharmacological management of COPD. Dual bronchodilation with umeclidinium/vilanterol (UMEC/VI; 62.5/25 µg) is a novel LAMA/LABA combination approved for maintenance treatment patients Objective: The objective this study was assess cost-effectiveness UMEC/VI compared tiotropium (TIO) 18 µg, open dual LAMA + LABA treatment, or no bronchodilator in moderate very severe...

Pneumococcal diseases caused by Streptococcus pneumoniae represent a significant health and economic burden. Mexico has benefited from the inclusion of 7-valent (PCV7) 13-valent pneumococcal conjugate vaccines (PCV13) since their in National Immunization Program (NIP) 2006 2010, respectively. The objective this study is to estimate impact existing program predict future implications change current program.A previously published model was updated historic PCV programs relative pre-PCV...

Abstract The 13-valent pneumococcal conjugate vaccine (PCV) has been part of routine immunisation in a 2 + 1 schedule (two primary infant doses and one booster during the second year life) UK since 2010. Recently, UK's Joint Committee on Vaccination Immunisation recommended changing to while conceding that this will increase disease burden; however, uncertainty remains how much burden – including invasive (IPD) non-invasive increase. We built dynamic transmission model investigate question....

Psoriasis is a long-term inflammatory skin disorder, with negative effects on employment, relationships and social function, frequently causing reduced quality of life. People psoriasis often present to secondary care late into their condition but the reasons for this are unknown.To examine patient pathway, health-seeking behaviour drivers referral in patients psoriasis.Sixteen mild-to-severe psoriasis, newly referred participated semi-structured interview. Scripts were analysed by thematic...

Objective: To examine the clinical and economic impact of vedolizumab compared with conventional therapy in treatment moderately-to-severely active ulcerative colitis (UC) UK based on results GEMINI I trial. Methods: A decision-analytic model Microsoft Excel was used to compare (aminosalicylates, corticosteroids, immunomodulators) for patients UC UK. We considered following three populations: overall intent-to-treat population from trial, naïve anti-TNF therapy, those who had failed...

A model was developed to estimate the historical impact (including total societal health and economic benefit) of pneumococcal conjugate vaccine (PCV) programs in overall Canadian population between 2005 2015, inclusively. Historical incidence invasive disease (IPD), pneumonia, acute otitis media (AOM) were obtained from epidemiologic databases supplemented with published unpublished data. Two scenarios considered: (1) observed 2015 setting PCV use; (2) a hypothetical scenario which we...

Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence relapses. Aripiprazole once-monthly (AOM) has been shown reduce total psychiatric hospitalizations among patients who switched from oral standard care (SOC) therapy AOM in a multicenter, open-label, mirror-image study schizophrenia. Because the increasing need improve patient outcomes while containing costs, it important understand impact treatment initiation on medical...

Since 2010, 10-valent (PCV10) and 13-valent pneumococcal conjugate vaccines (PCV13) have been available as part of infant national immunization programs. Belgium is one the few countries that implemented PCV13 (2007-2015), switched to PCV10 (2015-2018) then back (2018-present) after observing increases in disease. We assessed impacts both historical prospective PCV choice context Belgian health care system used this experience validate previously developed economic models.Using incidence...